REM3
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
08/06/2026
Voltar para busca
Dado oficial do USPTO
INPHARMA RESEARCH · DEVELOP PRODUCE
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: MistaEscritório: US
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
31
Atualização mais recente
09/06/2026
Classificação
Registrada
Tipo de marca
Mista
Classes Nice
5
Data de depósito
30/09/2019
Data de registro
08/06/2021
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
08/06/2021
Última transação
09/06/2026
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Código do desenho
3
Tipo de titular
09
Localização do titular
IT
Examinador
VAN DEN ABEELEN, DEREK C
Unidade examinadora
N80
Localização atual
PUBLICATION AND ISSUE SECTION
Descrição da marca
The mark consists of a design of four rectangles with two curved corners each, wherein the top left rectangle is in gold and is larger than the other three rectangles, and the other three rectangles are in blue, and wherein the rectangles design is to the left of the wording "INPHARMA", wherein the wording "IN" is in gold and "PHARMA" is in blue, above the wording "RESEARCH DEVELOP PRODUCE" in blue with blue dots between this wording.
Titulares e representantes
Titulares
Inpharma S.p.A.
Representantes
Francesco Braga Perani & Partners S.p.A.
Classificação técnica
Classes Nice
Classe 5
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 5
Foodstuffs and dietetic substances for medical and veterinary purposesdietary supplementsfood grade products being capsules sold empty for pharmaceuticalsinfant food for medical purposesOrganic food supplementsorganic dietary supplementspowder food supplementsliquid food supplementsdietary supplements that are sold in a container cap for subsequent delivery into liquidsnewborn food supplementsinfant food supplementswellness dietary supplementsnatural dietary supplements for the treatment of the mental healthnutritionally complete dietetic foods with a standard nutrient formulation adapted for medical purposesnutritionally complete dietetic foods with a nutrient-adapted formulation specific for a diseasenutritionally incomplete dietetic foods with a standard formulation or a nutrient-adapted formulation specific for a disease; dietetic and nutritional preparations for medical use; infant formula; dietetic substances for babies for medical purposes; dietary supplements for infants; dietary supplements for humans and animals; food supplements; dietary food supplementsnot for medical purposes; dietary supplements; nutritional supplements; dietary supplement drink mixes; dietary supplemental drinks; dietetic beverages adapted for medical purposes; multi-vitamin preparations; vitamins and vitamin preparations; dietary supplements for athletes; powdered nutritional supplement drink mix; dietetic foodstuffs for medical purposesdietary supplements; probiotic supplements; prebiotic supplements; probiotic bacterial formulations for medical useprobiotic supplements; probiotic preparations for medical use to help maintain a natural balance of flora in the digestive system; milk ferments for pharmaceutical purposes; pharmaceutical preparations and substances for treating constipation or diarrhoea; pharmaceutical preparations and substancesAntioxidantsnutritional supplements for boosting energyMultivitaminsSleeping pills/tabletsImmunostimulantsoral Rehydration saltsVitaminsskin Enhancers being medicated skin care preparationsNasal spraysAmino acidsAntiemetic preparationsnutritional supplements consisting primarily of ironAnti-inflammatorieslozenges to relieve sore throatcough syrupsanti-obesity diet capsules; medicinal preparations and substances for treating constipation or diarrhoea; medicinal preparations and substancesnutritional supplements for boosting energyMultivitaminsSleeping pills/tabletsImmunostimulantsoral Rehydration saltsVitaminsskin Enhancers being medicated skin care preparationsNasal spraysAmino acidsAntiemetic preparationsnutritional supplements consisting primarily of ironAnti-inflammatorieslozenges to relieve sore throatcough syrupsanti-obesity diet capsules; antibacterial substances for medical purposes; diagnostic substances for medical use; astringents for medical purposes; pharmaceutical antiallergic preparations and substances; bactericides; medical devices based on substancesdelivery agents in the form of dissolvable films that facilitate the delivery of nutritional supplementsnasal sprays for cold symptomssprays to relieve sore throat
Publicações
Histórico de despachos e eventos da marca no USPTO.
31 publicações encontradas
NREP
NEW REPRESENTATIVE AT IB RECEIVED
30/04/2026
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
24/10/2021
FICS
FINAL DISPOSITION NOTICE SENT TO IB
28/09/2021
FIMP
FINAL DISPOSITION PROCESSED
27/09/2021
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
08/09/2021
R.PR
REGISTERED-PRINCIPAL REGISTER
08/06/2021
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
23/03/2021
PUBO
PUBLISHED FOR OPPOSITION
23/03/2021
GPNX
NOTIFICATION PROCESSED BY IB
21/03/2021
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
03/03/2021
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
03/03/2021
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
03/03/2021
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
18/02/2021
XAEC
EXAMINER'S AMENDMENT ENTERED
18/02/2021
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
18/02/2021
GNEA
EXAMINERS AMENDMENT E-MAILED
18/02/2021
CNEA
EXAMINERS AMENDMENT -WRITTEN
18/02/2021
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
09/02/2021
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
09/02/2021
ALIE
ASSIGNED TO LIE
06/02/2021
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
03/11/2020
RFNT
REFUSAL PROCESSED BY IB
23/05/2020
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
03/05/2020
RFRR
REFUSAL PROCESSED BY MPU
03/05/2020
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
22/04/2020
CNRT
NON-FINAL ACTION WRITTEN
21/04/2020
MAFR
APPLICATION FILING RECEIPT MAILED
04/04/2020
DOCK
ASSIGNED TO EXAMINER
31/03/2020
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
31/03/2020
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
26/03/2020
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace INPHARMA RESEARCH · DEVELOP PRODUCE ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.